ShockWave Medical, Inc. (SWAV): Price and Financial Metrics
SWAV Stock Summary
- Shockwave Medical Inc's stock had its IPO on March 7, 2019, making it an older stock than merely 4.1% of US equities in our set.
- SWAV's price/sales ratio is 54.12; that's higher than the P/S ratio of 94.84% of US stocks.
- As for revenue growth, note that SWAV's revenue has grown 57.92% over the past 12 months; that beats the revenue growth of 91.13% of US companies in our set.
- Stocks that are quantitatively similar to SWAV, based on their financial statements, market capitalization, and price volatility, are AEHR, RKDA, NURO, BHVN, and AMSC.
- SWAV's SEC filings can be seen here. And to visit Shockwave Medical Inc's official web site, go to www.shockwavemedical.com.
SWAV Stock Price Chart Interactive Chart >
SWAV Price/Volume Stats
| Current price | $99.43 | 52-week high | $143.79 |
| Prev. close | $98.42 | 52-week low | $22.01 |
| Day low | $95.57 | Volume | 122,104 |
| Day high | $99.81 | Avg. volume | 427,018 |
| 50-day MA | $120.10 | Dividend yield | N/A |
| 200-day MA | $79.19 | Market Cap | 3.46B |
ShockWave Medical, Inc. (SWAV) Company Bio
Shockwave Medical, Inc. operates as a medical device company. It focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease. The company was founded by Daniel Hawkins, John M. Adams, and Todd J. Brinton in 2009 and is headquartered in Santa Clara, CA.
Latest SWAV News From Around the Web
Below are the latest news stories about Shockwave Medical Inc that investors may wish to consider to help them evaluate SWAV as an investment opportunity.
ShockWave Medical: Transformative Potential, But Much Upside Is Already Baked InInvestment Thesis Lately, ShockWave Medical (SWAV) seems to be falling out of favor with the investors. Although the stock has gained 206% in the last year and 18.5% YTD (year-to-date), the stock is down 13.5% from its high of $142.05 as of January 19, 2021. ShockWave's fourth-quarter revenues jumped 59%... |
How to Sleep Soundly When One of Your Big Stocks Has a Really Bad DayIn this video clip from Motley Fool Live, recorded on Feb. 18, Fool.com contributors Brian Feroldi, Brian Withers, and Matt Frankel, CFP, discuss how to sleep soundly even when your portfolio loses $10,000 over the course of a few days. Matt Frankel: I see a question that I'd really like to address because it's a very important concept. |
ShockWave Medical, Inc. (SWAV) CEO Doug Godshall on Q4 2020 Results - Earnings Call TranscriptShockWave Medical, Inc. (SWAV) Q4 2020 Results Earnings Conference Call February 17, 2021, 4:30 pm ET Company Participants Debbie Kaster - Vice President of Investor Relations Doug Godshall - President, Chief Executive Officer Isaac Zacharias - Chief Commercial Officer Dan Puckett - Chief Financial Officer Conference Call Participants David Lewis... |
Shockwave Medical gets FDA nod for intravascular lithotripsy for heart diseaseShockwave Medical Inc. said Tuesday that its intravascular lithotripsy (IVL) therapy has won U.S. FDA approval for the treatment of severe coronary artery disease (CAD). The technology, which was granted breakthrough device designation in 2019, is a novel application of lithotripsy, which has long been used to safely shatter kidney stones. |
Shockwave Intravascular Lithotripsy FDA Approved to Treat Advanced Heart DiseaseTransformative Technology Now Available for Calcified Coronary PlaqueSANTA CLARA, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company’s sonic pressure wave therapy received Pre-Market Approval for severely calcified coronary artery disease from the U.S. Food and Drug Administration (FDA). The innovative technology, which was granted Breakthrough Device designation by the FDA, is a novel application of lithotripsy, an approach that has been used for decades to safely break up kidney stones. With this approval, IVL is now commercially available in the United States to treat problematic calcium in the coronary art... |
SWAV Price Returns
| 1-mo | -22.12% |
| 3-mo | 4.00% |
| 6-mo | 53.68% |
| 1-year | 151.79% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -4.14% |
| 2020 | 136.16% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...